Logo image of NUVO

HOLDCO NUVO GROUP DG LTD (NUVO) Stock Fundamental Analysis

NASDAQ:NUVO - Nasdaq - IL0012023656 - Common Stock - Currency: USD

0.17  -0.05 (-23.56%)

After market: 0.2 +0.03 (+17.65%)

Fundamental Rating

1

Overall NUVO gets a fundamental rating of 1 out of 10. We evaluated NUVO against 189 industry peers in the Health Care Equipment & Supplies industry. While NUVO seems to be doing ok healthwise, there are quite some concerns on its profitability. NUVO is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year NUVO has reported negative net income.
NUVO had a negative operating cash flow in the past year.
NUVO Yearly Net Income VS EBIT VS OCF VS FCFNUVO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2021 2022 2023 0 2M -2M -4M -6M -8M

1.2 Ratios

The Return On Assets of NUVO (-10.78%) is comparable to the rest of the industry.
NUVO has a Return On Equity of -25.68%. This is comparable to the rest of the industry: NUVO outperforms 57.67% of its industry peers.
Industry RankSector Rank
ROA -10.78%
ROE -25.68%
ROIC N/A
ROA(3y)-3.34%
ROA(5y)N/A
ROE(3y)-8.29%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
NUVO Yearly ROA, ROE, ROICNUVO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2021 2022 2023 0 -5 -10 -15 -20 -25

1.3 Margins

NUVO does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
NUVO Yearly Profit, Operating, Gross MarginsNUVO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2021 2022 2023

More info and screens

4

2. Health

2.1 Basic Checks

The number of shares outstanding for NUVO has been reduced compared to 1 year ago.
NUVO has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
NUVO Yearly Shares OutstandingNUVO Yearly Shares OutstandingYearly Shares Outstanding 2021 2022 2023 5M 10M 15M 20M 25M
NUVO Yearly Total Debt VS Total AssetsNUVO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2021 2022 2023 50M 100M 150M 200M 250M

2.2 Solvency

NUVO has an Altman-Z score of -1.73. This is a bad value and indicates that NUVO is not financially healthy and even has some risk of bankruptcy.
NUVO has a worse Altman-Z score (-1.73) than 62.96% of its industry peers.
There is no outstanding debt for NUVO. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -1.73
ROIC/WACCN/A
WACCN/A
NUVO Yearly LT Debt VS Equity VS FCFNUVO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2021 2022 2023 0 50M 100M 150M 200M 250M

2.3 Liquidity

A Current Ratio of 0.03 indicates that NUVO may have some problems paying its short term obligations.
Looking at the Current ratio, with a value of 0.03, NUVO is doing worse than 98.41% of the companies in the same industry.
NUVO has a Quick Ratio of 0.03. This is a bad value and indicates that NUVO is not financially healthy enough and could expect problems in meeting its short term obligations.
NUVO has a worse Quick ratio (0.03) than 98.41% of its industry peers.
Industry RankSector Rank
Current Ratio 0.03
Quick Ratio 0.03
NUVO Yearly Current Assets VS Current LiabilitesNUVO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2021 2022 2023 1M 2M 3M 4M 5M

More info and screens

0

3. Growth

3.1 Past

NUVO shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -362.49%.
EPS 1Y (TTM)-362.49%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%N/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
NUVO Yearly Revenue VS EstimatesNUVO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2021 2022 2023
NUVO Yearly EPS VS EstimatesNUVO Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

NUVO reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
NUVO Price Earnings VS Forward Price EarningsNUVO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
NUVO Per share dataNUVO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.1 -0.1 0.2 0.3 0.4

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

NUVO does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

HOLDCO NUVO GROUP DG LTD

NASDAQ:NUVO (8/30/2024, 10:08:58 PM)

After market: 0.2 +0.03 (+17.65%)

0.17

-0.05 (-23.56%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)N/A N/A
Earnings (Next)N/A N/A
Inst OwnersN/A
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap5.65M
AnalystsN/A
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.42
P/tB 0.42
EV/EBITDA N/A
EPS(TTM)-0.17
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-0.02
FCFYN/A
OCF(TTM)-0.02
OCFYN/A
SpS0
BVpS0.41
TBVpS0.41
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -10.78%
ROE -25.68%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-3.34%
ROA(5y)N/A
ROE(3y)-8.29%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.03
Quick Ratio 0.03
Altman-Z -1.73
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-362.49%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%N/A
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-411.88%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-28.71%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-28.71%
OCF growth 3YN/A
OCF growth 5YN/A